Protein-Based Nanoparticles as Drug Delivery Systems
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Seyoung | - |
dc.contributor.author | Choi, Dong Wook | - |
dc.contributor.author | Kim, Hong Nam | - |
dc.contributor.author | Park, Chun Gwon | - |
dc.contributor.author | Lee, Wonhwa | - |
dc.contributor.author | Park, Hee Ho | - |
dc.date.accessioned | 2023-07-24T09:27:40Z | - |
dc.date.available | 2023-07-24T09:27:40Z | - |
dc.date.created | 2023-07-19 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/187335 | - |
dc.description.abstract | Nanoparticles have been extensively used as carriers for the delivery of chemicals and biomolecular drugs, such as anticancer drugs and therapeutic proteins. Natural biomolecules, such as proteins, are an attractive alternative to synthetic polymers commonly used in nanoparticle formulation because of their safety. In general, protein nanoparticles offer many advantages, such as biocompatibility and biodegradability. Moreover, the preparation of protein nanoparticles and the corresponding encapsulation process involved mild conditions without the use of toxic chemicals or organic solvents. Protein nanoparticles can be generated using proteins, such as fibroins, albumin, gelatin, gliadine, legumin, 30Kc19, lipoprotein, and ferritin proteins, and are prepared through emulsion, electrospray, and desolvation methods. This review introduces the proteins used and methods used in generating protein nanoparticles and compares the corresponding advantages and disadvantages of each. | - |
dc.publisher | MDPI | - |
dc.title | Protein-Based Nanoparticles as Drug Delivery Systems | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Hee Ho | - |
dc.identifier.doi | 10.3390/pharmaceutics12070604 | - |
dc.identifier.scopusid | 2-s2.0-85087164173 | - |
dc.identifier.wosid | 000557152600001 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.12, no.7, pp.1 - 29 | - |
dc.relation.isPartOf | PHARMACEUTICS | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 29 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SILK FIBROIN NANOPARTICLES | - |
dc.subject.keywordPlus | HUMAN SERUM-ALBUMIN | - |
dc.subject.keywordPlus | HIGH-DENSITY-LIPOPROTEIN | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE | - |
dc.subject.keywordPlus | GLIADIN NANOPARTICLES | - |
dc.subject.keywordPlus | PHYSICOCHEMICAL PROPERTIES | - |
dc.subject.keywordPlus | TARGETED DELIVERY | - |
dc.subject.keywordPlus | HSA-NANOPARTICLES | - |
dc.subject.keywordPlus | GENE DELIVERY | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordAuthor | protein nanoparticle | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | biocompatible | - |
dc.subject.keywordAuthor | biodegradable | - |
dc.subject.keywordAuthor | controlled release | - |
dc.identifier.url | https://www.mdpi.com/1999-4923/12/7/604 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.